Enliven Therapeutics ELVN Stock Issuance Proceeds
Stock Issuance Proceeds at other companies
Other financials
Where this comes from
Reported directly by Enliven Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromStockOptionsExercised.
The official record: Enliven Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Enliven Therapeutics's stock issuance proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Enliven Therapeutics's stock issuance proceeds?
- Enliven Therapeutics (ELVN) reported stock issuance proceeds of $10.05M in Q1 2026.
- How has Enliven Therapeutics's stock issuance proceeds changed year-over-year?
- Enliven Therapeutics's stock issuance proceeds increased by 4196.2% year-over-year, from $234K to $10.05M.
- What is the long-term trend for Enliven Therapeutics's stock issuance proceeds?
- Over 3 years (2021 to 2025), Enliven Therapeutics's stock issuance proceeds has grown at a 38.7% compound annual growth rate (CAGR), from $860K to $2.3M.
- What does stock issuance proceeds mean?
- Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.